A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Bristol-Myers Squibb
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Center Hospital East
Taiho Oncology, Inc.
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Astellas Pharma Inc
Vejle Hospital
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
Arcus Biosciences, Inc.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Pfizer
Roswell Park Cancer Institute
National Cancer Institute (NCI)
Akeso
Alliance for Clinical Trials in Oncology
Seagen Inc.
Astellas Pharma Inc
OncoSil Medical Limited
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Duke University
University of California, Irvine
Georgetown University
National Health Research Institutes, Taiwan
Memorial Sloan Kettering Cancer Center
OHSU Knight Cancer Institute
ImmunityBio, Inc.
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
University Health Network, Toronto
Enliven Therapeutics
City of Hope Medical Center
Thomas Jefferson University
Akeso
Bristol-Myers Squibb
Grupo Espanol Multidisciplinario del Cancer Digestivo
University of Rochester
ITM Solucin GmbH
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Pfizer